**PATENT** 

**DOCKET NO.:** AGIL-0043 **Application No.:** 10/621,711

Preliminary Amendment - First Action Not Yet Received

This listing of claims will replace all prior versions, and listings, of claims in the application.

## **Listing of Claims:**

- 1-162. (Canceled)
- 163. (New) A transdermal delivery system comprising a backing layer and an adhesive polymer matrix affixed to the backing layer, wherein the adhesive polymer matrix comprises:
  - (a) an adhesive polymer;
  - (b) a humectant;
  - (c) a combination of skin permeation enhancing agents comprising dimethyl sulfoxide; a fatty ( $C_8$ - $C_{20}$ ) alcohol ester of lactic acid; a lower ( $C_1$ - $C_4$ ) alkyl ester of lactic acid; and capric acid;
    - (d) a progestin; and
    - (e) an estrogen.
- 164. (New) The transdermal delivery system of claim 163, wherein the adhesive polymer is a polyacrylate copolymer, a polyisobutylene or a silicone adhesive.
- 165. (New) The transdermal delivery system of claim 164, wherein the polyacrylate copolymer comprises a 2-ethylhexyl acrylate monomer.
- 166. (New) The transdermal delivery system of claim 165, wherein the polyacrylate copolymer further comprises about 3 to 60% w/w vinyl acetate.
- 167. (New) The transdermal delivery system of claim 163, wherein the humectant comprises polyvinylpyrrolidone.
- 168. (New) The transdermal delivery system of claim 167, wherein the humectant comprises a polyvinylpyrrolidone copolymer.

PATENT

**DOCKET NO.:** AGIL-0043 **Application No.:** 10/621,711

Preliminary Amendment - First Action Not Yet Received

169. (New) The transdermal delivery system of claim 168, wherein the humectant is a polyvinylpyrrolidone/vinyl acetate copolymer.

- 170. (New) The transdermal delivery system of claim 169, wherein the polyvinylpyrrolidone is formulated in an amount of about 60% w/w and the vinyl acetate is formulated in an amount of about 40% w/w in the polyvinylpyrrolidone/vinyl acetate copolymer.
- 171. (New) The transdermal delivery system of claim 163, wherein the fatty alcohol ester of lactic acid is lauryl lactate.
- 172. (New) The transdermal delivery system of claim 163, wherein the lower alkyl ester of lactic acid is ethyl lactate.
- 173. (New) The transdermal delivery system of claim 163, wherein the progestin is levonorgestrel.
- 174. (New) The transdermal delivery system of claim 163, wherein the estrogen is ethinyl estradiol or 17  $\beta$ -estradiol.